Orforglipron — the next generation weight loss pill without injections
01 Mar
Orforglipron is the name that more and more people hear in connection with future obesity treatment. Developed by Eli Lilly, it represents a completely new type of GLP-1 drug: a small molecule in tablet form that can be taken once a day without food and water restrictions. Unlike Rybelsus, which requires an empty stomach and a 30-minute waiting period, orforglipron promises to make GLP-1 treatment as easy as taking a regular pill. We go through what the research shows, how far development has come and what it can mean for those who want to lose weight without injections or complicated dosing routines.
What is orforglipron and how is it different?
Orforglipron is a non-peptide, small molecule GLP-1 receptor agonist. It sounds technical, but the difference to existing GLP-1 drugs is fundamental and worth understanding.
All current GLP-1 drugs — semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatid (Mounjaro) — are peptides. They are based on modified versions of the body’s own hormones and consist of chains of amino acids. Peptides are delicate molecules that break down quickly in the gastrointestinal tract, which is why most GLP-1 preparations are given as injections. Rybelsus solves this through an absorption enhancer (SNAC) but with low bioavailability and strict absorption restrictions.
Orforglipron is not a peptide. It is a synthetic small molecule that is chemically completely different but binds to and activates the same GLP-1 receptor. The advantage of a small molecule: it is stable in stomach acid, is efficiently absorbed through the intestinal wall and does not require special intake conditions. You can take the tablet at any time of the day, with or without food, with any amount of liquid. It’s a trivial difference on paper but a huge practical advantage in everyday life.
An additional strategic advantage: small molecules are cheaper to manufacture on a large scale than biological peptides. Peptide production requires complex bioprocesses, strict cold chains and specialized facilities. A small molecule tablet can be manufactured using conventional pharmaceutical equipment and distributed without a cold chain — a logistical simplification that lowers costs throughout the chain from factory to pharmacy. If orforglipron is approved, Eli Lilly has flagged the possibility of offering the treatment at a lower price than current injectable preparations — something that could democratize access to GLP-1 treatment globally.
Clinical results — the ATTAIN studies
Orforglipron’s phase 3 weight loss program, called ATTAIN, has generated extensive data that was published in the New England Journal of Medicine in 2025.
ATTAIN-1 included just over 3,100 obese adults without diabetes. After 72 weeks of treatment, the results showed an average weight loss of 7.5% with the 6 mg dose, 8.4% with the 12 mg dose and 12.4% with the highest dose of 36 mg, compared to about 2% in the placebo group. Among participants on 36 mg, nearly 60% achieved a weight loss of at least 10% and approximately 40% achieved 15% or more.
ATTAIN-2 studied patients with both obesity and type 2 diabetes — a group that historically shows lower weight loss with GLP-1 therapy. Here, the highest dose achieved an average weight loss of 10.5% with a concomitant HbA1c reduction of 1.8 percentage points. Three out of four participants on 36 mg achieved HbA1c below 6.5%, which is below the diabetes threshold.
ATTAIN-MAINTAIN was a unique study that investigated whether patients could switch from injectable GLP-1 preparations (Wegovy or Zepbound/tirzepatid) to oral orforglipron and maintain their weight loss. The results, presented in December 2025, showed that the switch worked: patients who switched from Wegovy to orforglipron maintained essentially all of their weight loss over 52 weeks, while the placebo group regained significant weight. It opens up a treatment strategy where patients start with injections for maximum effect and then switch to tablets for long-term maintenance.
Orforglipron versus oral semaglutide — a head-to-head comparison
The ACHIEVE-3 study directly compared orforglipron with oral semaglutide (Rybelsus) in patients with type 2 diabetes. The results showed that orforglipron in both 12 mg and 36 mg produced better HbA1c reduction and weight loss than semaglutide in the 7 mg and 14 mg doses.
The differences were clinically relevant: orforgliprone 36 mg reduced HbA1c by 2.2 percentage points compared to 1.4 for semaglutide 14 mg. Weight loss was also clearly better with orforglipron. Add to that the practical advantage that orforgliprone does not require fasting or waiting time, and the picture of a potentially superior oral GLP-1 treatment begins to take shape.
However, it should be noted that the comparison applies to Rybelsus in its current maximum dose (14 mg). Novo Nordisk is developing a higher dose of oral semaglutide (50 mg) which in the OASIS 1 trial showed weight loss on par with injectable Wegovy. The direct competition between orforglipron 36 mg and oral semaglutide 50 mg remains to be studied — and that is where the real market battle will be.
Side effects and safety profile
The side effects of orforgliprone follow the familiar GLP-1 pattern, with the gastrointestinal tract being the primary problem area. Nausea, diarrhoea, vomiting and constipation were reported in the ATTAIN studies at frequencies broadly similar to injectable GLP-1 therapy. Most side effects were described as mild to moderate and were most common during dose escalation.
The proportion of patients who discontinued treatment due to adverse events was 5–10% in the orforgliprone groups compared with approximately 3% in the placebo group. It is comparable to or slightly better than the discontinuation rates of injectable weight loss drugs, suggesting that the oral route of administration does not result in poorer tolerability — quite the opposite in most comparisons.
One aspect that the EMA and FDA will scrutinize closely is liver safety. Eli Lilly has consistently reported that no liver safety signal was observed in any of the Phase 3 studies — but it’s an issue regulators take seriously for new small-molecule drugs, and post-marketing monitoring will likely include liver parameters.
When can orforglipron be available?
Eli Lilly submitted an application to the US FDA in late 2025, following the successful completion of ATTAIN-MAINTAIN. The company has also flagged global regulatory filings, including the EMA in Europe.
If the review process follows the normal schedule, an FDA approval could come in the second half of 2026 or early 2027. EU approval via the EMA usually comes 6-12 months after the FDA, depending on the scope of the application and any supplementary issues. This means that orforglipron can realistically be available in Swedish pharmacies in 2027–2028 at the earliest.
In the meantime, the research program continues. Orforglipron is also being studied for obstructive sleep apnea, hypertension, knee joint arthrosis in obesity and cardiovascular outcomes — indications that could broaden the preparation’s area of use even further if the results are positive.
What orforglipron can mean for weight loss treatment
If orforglipron lives up to the promise of an effective, simple and affordable oral GLP-1 treatment, it could fundamentally change the landscape. The biggest barriers to GLP-1 treatment today are fear of injections, shortages in supply chains for biological peptides and cost. A small-molecule tablet that can be manufactured industrially on a large scale addresses all three problems.
For those already using alternatives to Ozempic orforglipron can be an interesting addition — especially as maintenance treatment after initial weight loss with injections. The ATTAIN-MAINTAIN study shows that the concept works clinically, and it remains to be seen how the pricing will land in practice.
Orforglipron is not yet approved and cannot be bought in Sweden. But for anyone following developments in the GLP-1 field, it’s hard not to see it as one of the most promising molecules in the pipeline — a pill that could potentially deliver injection-like results without a single needle.
.entry-content